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ABSTRACT
◥
Purpose: Immune-checkpoint inhibitors have shown therapeu-
tic efficacy in various malignant diseases. However, anti-
programmed death (PD)-1 therapy has not shown clinical efficacy
in multiple myeloma.
Experimental Design: Bone marrow (BM) mononuclear cells
were obtained from 77 newly diagnosedmultiplemyeloma patients.
We examined the expression of immune-checkpoint receptors in
BM CD8þ T cells and their functional restoration by ex vivo
treatment with anti–PD-1 and TGFb inhibitors.
Results: We confirmed the upregulation of PD-1 and PD-L1
expression in CD8þ T cells and myeloma cells, respectively, from
the BM of multiple myeloma patients. PD-1–expressing CD8þ T
cells from the BM of multiple myeloma patients coexpressed other
checkpoint inhibitory receptors and exhibited a terminally dif-
ferentiated phenotype. These results were also observed in BM
CD8þ T cells specific to myeloma antigens NY-ESO-1 and
HM1.24. BM CD8þ T cells from multiple myeloma patients
exhibited reduced proliferation and cytokine production upon
T-cell receptor stimulation. However, anti–PD-1 did not increase
the proliferation of BM CD8þ T cells from multiple myeloma
patients, indicating that T-cell exhaustion in multiple myeloma is
hardly reversed by PD-1 blockade alone. Intriguingly, anti–PD-1
significantly increased the proliferation of BM CD8þ T cells from
multiple myeloma patients in the presence of inhibitors of TGFb,
which was overexpressed by myeloma cells.
Conclusions: Our findings indicate that combined blockade of
PD-1 and TGFb may be useful for the treatment of multiple
myeloma.
Introduction
Multiple myeloma is a plasma cell malignancy and the second most
common hematologic cancer (1). Although the introduction of novel
therapeutic agents, such as immunomodulatory drugs (IMiD) and
proteasome inhibitors, and increased use of autologous stem cell
transplantation have improved survival in patients with multiple
myeloma, most patients relapse after remission or are refractory to
treatment (2, 3). Multiple myeloma still remains an incurable disease,
and alternative therapeutic options are necessary for multiple mye-
loma patients.
Immune-checkpoint inhibitors (ICI), including blocking antibodies
against programmed death (PD)-1 or PD-ligand 1 (PD-L1), become
paradigm-shifting treatment in solid cancers. It is remarkable that,
once patients achieve a clinical response with ICIs, they tend to show
long-term durable disease control (4). Therefore, ICIs are attractive
therapeutic options for multiple myeloma patients suffering from
frequent relapses.
The rationale for targeting PD-1 and PD-L1 in multiple myeloma
therapy was investigated previously. PD-L1 is expressed on malignant
plasma cells from multiple myeloma patients, but not on aberrant
plasma cells from patients with monoclonal gammopathy of unde-
termined significance (MGUS) or normal plasma cells (5, 6). PD-1
expression is also increased in CD8þ and CD4þ T cells from multiple
myeloma patients compared with those from healthy donors (7–9).
Moreover, blocking PD-1 and PD-L1 interaction restored antitumor
effector functions and the cytotoxicity of T cells from multiple
myeloma patients in ex vivo assays (10).
However, a phase I clinical trial evaluating anti–PD-1monotherapy
in patients with relapsed or refractory hematologic malignancies
revealed no objective response in multiple myeloma patients (11).
A recent study tried to explain the low response of anti–PD-1 mono-
therapy inmultiplemyeloma patients by showing that expanded T-cell
clones in multiple myeloma patients express low levels of PD-1 and
represent senescent phenotypes rather than exhaustion (12). To
overcome the limitation of anti–PD-1 monotherapy in multiple
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myeloma, the phenotype and differentiation of CD8þT cells need to be
characterized in the bonemarrow (BM) of multiple myeloma patients,
particularly by analyzing myeloma antigen–specific CD8þ T cells. In
addition, the role of immunosuppressive factors abundant in theBMof
multiple myeloma patients needs to be considered, including trans-
forming growth factor-b (TGFb). Recent studies reported that TGFb
attenuated anti–PD-L1-induced antitumor responses in patients with
metastatic urothelial cancer (13), and coinhibition of TGFb and PD-1
triggered robust tumor regression in mouse models (13, 14).
In the present study, we investigated the expression of immune-
checkpoint inhibitory receptors, including PD-1, T-cell immunoglob-
ulin and mucin-domain containing-3 (Tim-3), lymphocyte activation
gene-3 (Lag-3), and T-cell immunoglobulin and immunoreceptor
tyrosine-based inhibitorymotif domain (TIGIT), and T-cell transcrip-
tion factors, including Eomesodermin (Eomes) and T-box transcrip-
tion factor TBX21 (T-bet), in BMCD8þTcells frommultiplemyeloma
patients. Moreover, we examined CD8þ T cells specific to myeloma
antigens, such as NY-ESO-1 and HM1.24, using major histocompat-
ibility complex class I (MHC-I) multimers. Importantly, we evaluated
the proliferation of BM CD8þ T cells frommultiple myeloma patients
following PD-1 blockade in direct ex vivo assays. We found that
coblockade of PD-1 and TGFb restores the function of BM CD8þ T
cells, whereas PD-1 blockade alone does not.
Materials and Methods
Patients and specimens
BM aspirates and paired peripheral blood (PB) samples were
collected from 77 newly diagnosed multiple myeloma patients (Sup-
plementary Table S1) at Chungnam National University Hospital
(Daejeon, Republic of Korea). BM mononuclear cells (BMMCs) and
PB mononuclear cells (PBMCs) were isolated by Ficoll (GE Health-
care: 17-5442-02) density-gradient centrifugation and cryopreserved
as previously described (15). BM aspirates were also collected from
patients with extranodal marginal zone B-cell lymphoma (EMZL; n¼
18; Supplementary Table S2), MGUS (n ¼ 10), and smoldering
multiple myeloma (SMM; n¼ 7; Supplementary Table S3). All EMZL
patients were confirmed as having no BM involvement and were
treated only with local treatment. To compare multiple myeloma with
other BM-involving B-cell lymphomas, we also obtained BM aspirates
from treatment-na€ve diffuse large B-cell lymphoma (DLBCL) and
Hodgkin lymphoma (HL) patients with BM involvement (n¼ 10 and
n¼ 2, respectively; Supplementary Table S4). This study was approved
by the institutional review boards of Chungnam National University
Hospital and was conducted in accordance with the Declaration of
Helsinki. Written informed consent was obtained from all patients.
Flow cytometry and immunophenotyping
Cryopreserved PBMCs and BMMCswere thawed and stained using
the Live/Dead fixable cell stain kit (Invitrogen: L34975 or L34971) to
exclude dead cells from the analysis. After washing with FACS staining
buffer, these cells were stained with fluorochrome-conjugated anti-
bodies for 20 minutes at room temperature. For intracellular staining,
surface-stained cells were fixed and permeabilized using a Foxp3
staining buffer kit (eBioscience: 00-5523-00) according to the man-
ufacturer's instructions. Multicolor flow cytometry was performed
using an LSR II flow cytometer (BD Biosciences), and the data were
analyzed by FlowJo V10 software (Treestar). Gating strategies for BM
CD8þ T cells (Supplementary Fig. S1), malignant and normal plasma
cells (Supplementary Fig. S2), and various immune cell subsets (Sup-
plementary Fig. S3) were provided.
Cell lines
IM-9 myeloma cells were purchased from the Korean Cell Line
Bank and grown in RPMI-1640 (Welgene: LM 011-01) supplemented
with 20% FBS (Sigma-Aldrich: 12003C) and 100 U/mL penicillin/
streptomycin (Welgene: LS202-02). IM-9 cells express HLA-A2
(Supplementary Fig. S4A) and PD-L1 (Supplementary Fig. S4B).
NY-ESO-1157-165–specific CD8
þ T cells were established as described
previously (16). Briefly, NY-ESO-1157-165–specific CD8
þ T cells from
HLA-A2þ donors were expanded in RPMI-1640 media containing
anti-CD3, IL2, IL7, IL15, and 10% FBS for 6 weeks using irradiated
autologous PBMCs as feeder cells. Purity of NY-ESO-1157-165–specific
CD8þ T cells was >95% (Supplementary Fig. S5A). When
NY-ESO-1157-165–specific CD8
þ T cells were cocultured with
NY-ESO-1157-165 peptide-pulsed IM-9 cells for 3 days, robust induc-
tion of PD-1 on CD8þ T cells was observed (Supplementary Fig. S5B).
Authentication of cell lines was not performed.
MHC-I multimers
To detect tumor antigen–specific CD8þ T cells, we used phycoer-
ythrin (PE)-conjugatedHLA-A0201 dextramers, includingNY-ESO-
1157-165 (SLLMWITQC) and HM1.2422-30 (LLLGIGILV) dextramers
(Immudex:WB2696 and custom ordered). A dextramer stain protocol
was applied to detect tumor antigen–specificCD8þT cells (17). Briefly,
BMMCs were incubated with 50 nmol/L dasatinib (Axon Medchem:
1392) in 1% FBS-PBS for 30 minutes at 37C, and then stained with
dextramer without washing for 15 minutes to prevent T-cell receptor
downregulation followingMHC-I multimer binding (18). After wash-
ing two timeswith FACS staining buffer, anti-PE antibody (BioLegend:
408101; clone PE001) was incubated for 20 minutes on ice. After
washing with FACS staining buffer, dextramer-stained cells were
processed sequentially in the Live/Dead cell stain, surface stain, and
intracellular stain steps as described previously. Among 77 patients
with multiple myeloma, 40 patients were HLA-A2þ, and we applied
HLA-A0201 NY-ESO-1157-165 and HM1.2422-30 dextramers to
BMMCs from 29 and 12 HLA-A2þ patients with multiple myeloma,
respectively. BM CD8þ T cells from 20 patients had > 40 of NY-ESO-
1157-165 dextramer
þ cells, and BM CD8þ T cells from 4 patients had
>40 of HM1.2422-30 dextramerþ cells. To detect human cytomegalo-
virus (HCMV) pp65-specific CD8þ T cells, PE-conjugated HLA-
A0201 dextramer loaded with HCMV pp65495-503 (NLVPMVATV)
was used (Immudex: WB2132).
Translational Relevance
Anti–PD-1 or anti–PD-L1 blocking antibodies are used for the
treatment of various malignancies. However, clinical trials of anti–
PD-1 have not shown therapeutic efficacy in patients with multiple
myeloma. In the present study, we examined the expression of
immune-checkpoint inhibitory receptors and the differentiation
status of bonemarrow–infiltrating CD8þT cells frompatients with
multiple myeloma. In addition, we attempted to reinvigorate bone
marrowCD8þTcells by ex vivo treatmentwith anti–PD-1 blocking
antibodies. Anti–PD-1 treatment restored the proliferation and
effector cytokine production of bone marrow CD8þ T cells in the
presence of agents blocking the effect of TGFb, which was over-
expressed by myeloma cells. This study provides a rationale for
combined blockade of PD-1 and TGFb for the treatment of
multiple myeloma.
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Antibodies
The following fluorochrome-conjugated monoclonal antibodies
were used for multicolor flow cytometry: anti-CD3-Brilliant Violet
(BV) 786 (563800; clone SK7), anti-CD4-BV605 (562658; clone RPA-
T4), anti-CD8-AlexaFluor700 (557945; clone RPA-T8), anti-CD11c-
BV650 (563404; clone B-ly6), anti-CD14-PE-Cy7 (562698; clone
M5E2), anti-CD15-APC (555401; clone HI98), anti-CD19-BV605
(562653; clone SJ25C1), anti-CD30-FITC (341644; clone Ber-H83),
anti-CD38-Brilliant Blue 515 (564498; clone HIT2), anti-CD45-
BV786 (563716; clone HI30), anti-CD56-BV711 (563169; clone
NCAM16.2), anti-HLA-A2 (551285; clone BB7.2), anti-Ig, k Light
Chain-BV510 (563213; clone G20-193), anti-Ig, l Light Chain-FITC
(555796; clone JDC-12), anti–PD-L1-BV421(563738; clone MIH1; all
from BD Biosciences); anti–PD-1-BV421 (329920; clone EH12.2H7),
anti–Tim-3-PE (345012; clone F38-2E2), anti–Tim-3-PE/Dazzle594
(345034; clone F38-2E2; all from BioLegend); anti-HLA-DR-APC-
eFluor780 (47-9956-42; clone LN3), anti-Lag-3-APC (17-2239-42;
clone 3DS223H), anti-TIGIT-PerCP-eFluor710 (46-1550-42; clone
MBSA43; all from eBioscience). For intracellular staining, anti-T-
bet-PE-Cy7 (25-5825-82; clone 4B10) and anti-Eomes-FITC or
-eFluor660 (11-4877-42 or 50-4487-42; clone WD1928; all from
eBioscience); anti-TCF-1/TCF-7 (2203; clone C63D9; from Cell
Signaling Technology) were used.
Ex vivo stimulation of T cells and intracellular cytokine staining
Cryopreserved BMMCs were thawed and incubated overnight in
complete RPMI-1640 medium. The 96-well flat-bottom plate was
precoated with 1 mg/mL anti-CD3 (eBioscience: 16-0037-81; clone
OKT3) and 1 mg/mL anti-CD28 (BioLegend: 302933; clone CD28.2).
After incubating for 24 hours, Brefeldin A (BD Biosciences: 555029)
and monensin (BD Biosciences: 554724) were added for intracellular
accumulation of cytokine protein. After another 6 hours of incubation,
cells were stained using a Live/Dead fixable cell stain kit and then
stained with fluorochrome-conjugated antibodies against surface
markers, including anti-CD3-BV786 and anti-CD8-BV711 (BD Bios-
ciences: 563677; clone RPA-T8). Surface-stained cells were fixed and
permeabilized using the Foxp3 staining buffer kit and stained with
anti-TNF-FITC (BD Biosciences: 554512; Mab11) and anti-IFNg-PE-
Cy7 (BD Biosciences: 557844; 4S.B3).
TGFb1 intracellular cytokine staining
For enumeration of TGFb1-producing CD38þCD319þ plasma
cells, including myeloma cells, 1  106 BMMCs were cultured in a
96-well round-bottom plate in RPMI-1640 containing 10% FBS.
Brefeldin A and monensin were added 1 hour after incubation. After
another 5 hours of incubation, the BMMCs were harvested and
counted using an automatic cell counter (Cellometer Auto 2000;
Nexcelom). The harvested BMMCs were stained using the Live/Dead
fixable cell stain kit and then stained with fluorochrome-conjugated
antibodies against surface markers. Surface-stained cells were fixed
and permeabilized using the Foxp3 staining buffer kit and stained with
anti-BV421-TGFb1 (BD Biosciences: 562962; TW4-9E7).
T-cell proliferation assay
To evaluate functional restoration of T cells, we performed T-cell
proliferation assay with anti–PD-1 blocking antibodies and/or TGFb
inhibitors (19, 20). Cryopreserved BMMCs were thawed and incu-
bated overnight in complete RPMI-1640 medium. The BMMCs were
labeled with CellTrace Violet (CTV; Invitrogen: C34557) in PBS
containing 5% FBS for 20 minutes at 37C and stimulated with
1 ng/mL of anti-CD3. After 108 hours, the BMMCs were harvested
and stained with Live/Dead cell stain and surface antibodies for flow-
cytometric analysis. For tumor antigen peptide stimulation, NY-ESO-
1157-165 (SLLMWITQC) and HM1.2422-30 (LLLGIGILV) epitope pep-
tides (customized from Peptron) were added to CTV-labeled BMMCs
at 1 mg/mL and incubated in RPMI-1640 containing 10% FBS for
6 days. Media containing 5 mg/mL of anti–PD-1 (BioLegend: 329943;
EH12.2H7), anti-TGFb1 (BioLegend: 521703; 19D8), or mouse IgG1
isotype control (Miltenyi Biotec: 130-106-545; clone IS5-21F5) anti-
body, or 1 mmol/L of galunisertib, a TGFb receptor-1 inhibitor
(LY2157299, purchased from Selleckchem Chemicals) was added to
the culture.
To measure T-cell proliferation accurately, the mitotic index (21)
was calculated as follows: Mitotic index ¼ (Total number of




0 ðXnðTÞ2n Þ, where XnðTÞ is the absolute number
of daughter T cells in each division peak n.
Ex vivo expansion of antigen-specific BM CD8þ T cells
BMMCs from HLA-A2þ multiple myeloma patients were stimu-
lated with NY-ESO-1157-165, HM1.2422-30, or HCMV pp65495-503
peptides in RPMI-1640 supplemented with IL2, IL7, IL15, and 10%
FBS in the presence of anti–PD-1, TGFb inhibitors such as anti–
TGFb1-neutralizing antibody or galunisertib, or isotype control for
3 weeks, and the frequency of antigen-specific CD8þ T cells was
examined by MHC-I multimer staining.
In vitro cytotoxicity assay and intracellular cytokine staining
IM-9 target cells were labeled with PKH26 dye (Sigma-Aldrich:
PKH26GL) according to the manufacturer's instructions and pulsed
with 10 mg/mL of NY-ESO-1157-165 peptide for 1 hour at 37C in a 5%
CO2 incubator. Then target cells were cocultured with the same
number of NY-ESO-1157-165–specific PD-1
þCD8þ T cells (effector to
target ratio 1:1) in the absence or presence of anti–PD-1 blocking
antibodies and/or TGFb inhibitors. After 6 hours, cells were harvested
and stained with TO-PRO-3 (Thermo Fisher Scientific: T3605) to
detect dead target cells. For intracellular cytokine staining, brefeldin A
and monensin were added during 6 hours of incubation.
Analysis of KRAS mutation in multiple myeloma specimens and
measurement of T-cell response to KRAS G12D mutation
Multiplemyeloma cells were isolated fromBM samples with CD138
microbead (Miltenyi: 130-051-301) and subjected to Sanger sequenc-
ing after DNA isolation and amplification (forward sequence:
CCTGACATACTCCCAAGGAAA; backward sequence: CTTAAGC-
GTCGATGGAGGAG) to investigate KRAS mutation. CTV-labeled
BMMCs frommultiplemyeloma patients with orwithout KRASG12D
mutation were stimulated with a mixture of 9 overlapping peptides
(9-mer) spanning KRAS codon 12 of wild-type (YKLVVV-
GAGGVGKSALT; customized from Peptron) or mutant-type
(YKLVVVGADGVGKSALT; customized from Peptron) at 1 mg/mL
for each peptide and incubated in RPMI-1640 containing 10% FBS.
Cellular proliferation was measured with CTV dilution among CD8þ
T cells upon stimulation with a mixture of overlapping peptides after
144 hours.
In vitro treatment of TGFb1
BMCD8þT cells were purifiedwithCD8microbead (Miltenyi: 130-
045-201) and stimulated with plate-bound anti-CD3 (1 mg/mL), anti-
CD28 (1 mg/mL), and PD-L1 (10 mg/mL, Sino Biological: 10084-
H02H) in the presence or absence of TGFb1 (50 ng/mL, PeproTech:
100-21). After 30 hours, the expression of PD-1 and T-bet in CD8þ
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T cells was investigated. In addition, BMMCs were stimulated with
anti-CD3 (1 ng/mL) in the presence or absence of anti-TGFb antibody.
After 36 hours, the expression of PD-1, T-bet, and TCF-1 in CD8þ
T cells was investigated.
In vivo mouse model
MOPC315.BM murine myeloma cells were grown in RPMI-1640
supplementedwith 10%FBS, 100U/mLpenicillin/streptomycin, and 2
mmol/L L-glutamine (Thermo Fisher Scientific: 25030081) as previ-
ously described (22). Balb/cmice were purchased fromOrient and 6-to
8-week-old mice were used for all experiments. To establish an in vivo
plasmacytoma model, 1  106 MOPC315.BM myeloma cells were
subcutaneously injected. To test the therapeutic effect, isotype control
antibodies (Bio X Cell: BE0089), anti–PD-1 antibodies (Bio X Cell:
BE0146, 200 mg/mouse), anti-TGFb antibodies (Bio X Cell: BE0057,
200 mg/mouse), or a combination of anti–PD-1 with anti-TGFb
antibodies was administered once every 3 days from 11 days after
tumor injection. This study was approved by the Institutional Animal
Care and Use committee of Inje University College of Medicine.
Statistical analysis
Statistical analyses were performed using Prism software version 7.0
(GraphPad). The nonparametric Mann–Whitney U test was used to
compare two groups. Paired values were compared using the non-
parametric Wilcoxon matched-pairs signed rank test.
Results
Increased expression of PD-1 on BM CD8þ T cells from multiple
myeloma patients
In the flow-cytometric analysis of BMMCs frommultiple myeloma
patients, we gatedCD8þT cells (Supplementary Fig. S1) and examined
the expression of PD-1. The BM CD8þ T cells had a significantly
higher frequency of PD-1þ cells than paired PBCD8þT cells (Fig. 1A).
The frequency of PD-1þ cells among BM CD8þ T cells from multiple
myeloma patients was significantly higher than the frequency among
BM CD8þ T cells from patients with EMZL without BM involvement
(Fig. 1B). In addition, the frequency of PD-1þ cells among BM CD8þ
T cells from multiple myeloma patients was significantly higher than
the frequency among BMCD8þ T cells from patients withMGUS and
SMM, which are premalignant or precursors of multiple myeloma
(Fig. 1C). Taken together, the results confirm that BMCD8þ T cells in
multiple myeloma express increased levels of PD-1.
Next, we analyzed the coexpression of other immune-checkpoint
receptors, such as Tim-3, Lag-3, and TIGIT, on PD-1–expressing
CD8þ T cells from the BM of multiple myeloma patients. Among BM
CD8þ T cells, PD-1þ cells had significantly higher frequencies of Tim-
3þ, Lag-3þ, or TIGITþ cells than PD-1 cells (Fig. 1D and E). We also
examined the expression of T-cell transcription factors, such as T-bet
and Eomes, which are related to T-cell differentiation (23). In partic-
ular, an EomeshiT-betlo phenotype represents a terminally differenti-
ated status for CD8þ T cells, which is associated with poor reinvig-
oration of CD8þ T cells upon PD-1 blockade. In BMMCs from
multiple myeloma patients, PD-1þCD8þ T cells had a higher per-
centage of EomeshiT-betlo cells than PD-1CD8þ T cells (Fig. 1F and
G). In addition, TCF-1 expression was lower in PD-1þ cells than PD-
1 cells among BM-resident (CD69þ) CD8þ T cells (Fig. 1H). These
data demonstrate that PD-1–expressing CD8þ T cells from the BM of
multiple myeloma patients exhibit a terminally differentiated pheno-
type with coexpression of multiple immune-checkpoint inhibitory
receptors.
Increased expression of PD-1 on myeloma antigen–specific
CD8þ T cells
To examine the characteristics of myeloma antigen–specific
CD8þ T cells, we used HLA-A0201 dextramers loaded with NY-
ESO-1157-165 (24) or HM1.2422-30 (25) peptides. NY-ESO-1157-165–
and HM1.2422-30–specific CD8
þ T cells were successfully detected in
BMMCs from multiple myeloma patients (Fig. 2A). The frequency of
NY-ESO-1157-165– (Supplementary Fig. S6A) and HM1.2422-30 (Sup-
plementary Fig. S6B)–specific cells was higher in BM CD8þ T cells
frommultiple myeloma patients than in BMCD8þT cells from EMZL
patients without BM involvement, or patients with MGUS and SMM.
NY-ESO-1157-165– and HM1.2422-30–specific BM CD8
þ T cells from
multiple myeloma patients had significantly more PD-1þ cells than
total BM CD8þ T cells (Fig. 2B and C). In NY-ESO-1157-165– or
HM1.2422-30–specific CD8
þ T cells, PD-1þ cells had significantly
higher percentages of Tim-3þ, Lag-3þ, or TIGITþ cells than PD-1
cells (Fig. 2D and E). In an analysis of the differentiation status of
myeloma antigen–specific CD8þ T cells, PD-1þ cells expressed a
higher percentage of EomeshiT-betlo cells than PD-1 cells from the
BM of multiple myeloma patients (Fig. 2F). Taken together, the
results indicate that myeloma antigen–specific CD8þ T cells also
overexpress PD-1 and present a terminally differentiated
phenotype.
Expression of PD-L1 onmalignant plasma cells and immune cells
in BM from multiple myeloma patients
We also analyzed the expression of PD-L1 on BM cells
from multiple myeloma patients by gating malignant plasma
cells (CD38þCD319þCD45CD19) and normal plasma cells
(CD38þCD319þCD45þCD19þ; refs. 26, 27). Malignant plasma cells
had a single type of immunoglobulin light chain (kappa or lambda),
but normal plasma cells did not (Supplementary Fig. S2). The per-
centage of malignant plasma cells among BMMCs was 15.49% 
10.17% (mean standard deviation; Fig. 3A). Malignant plasma cells
had a significantly higher frequency of PD-L1þ cells than paired
normal plasma cells from multiple myeloma patients (Fig. 3B and
C). Malignant plasma cells frommultiple myeloma patients also had a
significantly higher frequency of PD-L1þ cells than normal plasma
cells from EMZL patients without BM involvement (Fig. 3D).
However, malignant plasma cells had a lower frequency of PD-L1þ
cells than BM malignant cells in DLBCL (CD45þCD19þCD20þk
or l LCþ cells) or HL (CD15þCD30þ Reed–Stenberg cells; Supple-
mentary Fig. S7A). We also analyzed the expression of PD-L1
on CD11cþ dendritic cells (CD45þCD14CD3CD11cþHLA-DRþ),
B cells (CD45þCD14CD3CD19þHLA-DRþ), and monocytes
(CD45þCD3CD14þ) from the BM of multiple myeloma, EMZL,
DLBCL, and HL patients. The frequencies of PD-L1þ cells in all three
subsets from the BM of multiple myeloma patients were significantly
higher than the frequency in tumor-free BM aspirates from EMZL
patients (Fig. 3E) and were comparable with those from the BM of
DLBCL and HL patients (Supplementary Fig. S7B). These results
demonstrate that PD-L1 is upregulated in the BM microenvironment
of multiple myeloma patients in addition to the upregulation of PD-1
on BM CD8þ T cells.
Impaired proliferation and cytokine production of BM CD8þ
T cells from multiple myeloma patients
As the expression of PD-1 and PD-L1 was upregulated in BM cells
frommultiple myeloma patients, we investigated the proliferation and
cytokine production of BM CD8þ T cells from multiple myeloma
patients. The BM CD8þ T cells from multiple myeloma patients
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exhibited significantly diminished anti-CD3–induced proliferation
compared with PB CD8þ T cells from the healthy donors (Supple-
mentary Fig. S8A) or multiple myeloma patients (Supplementary
Fig. S8B) or BM CD8þ T cells from EMZL patients without BM
involvement (Supplementary Fig. S8C) or MGUS/SMM patients
(Fig. 4A and B). In addition, we examined effector cytokine produc-
tion by BM CD8þ T cells from multiple myeloma patients. The
production of IFNg and TNF was analyzed by intracellular cytokine
staining and flow cytometry in response to anti-CD3 stimulation. The
percentage of IFNgþ, TNFþ, or double-positive (IFNgþTNFþ) cells
among BM CD8þ T cells was significantly lower in multiple myeloma
patients than in MGUS or SMM patients (Fig. 4C).
We also compared the functions of BM CD8þ T cells frommultiple
myeloma patients with those from patients with other B-cell lympho-
mas with BM involvement (DLBCL and HL). Interestingly, BM CD8þ
T cells from multiple myeloma patients proliferated significantly less
than those fromDLBCLorHLpatients (Fig. 4D andE).Moreover, BM
CD8þ T cells frommultiple myeloma patients exhibited a significantly
lower frequency of TNFþ or IFNgþTNFþ cells than those from
DLBCL or HL patients (Fig. 4F). Taken together, the results indicate
that BMCD8þT cells frommultiplemyeloma patients are functionally
impaired.
Failure of anti–PD-1-induced reinvigoration of BM CD8þ T cells
from multiple myeloma patients
Next, we tested whether PD-1 blockade restores the function of BM
CD8þ T cells from multiple myeloma patients. CTV-labeled BMMCs
were stimulated with anti-CD3 in the presence of anti–PD-1 blocking
or isotype control antibodies, and the proliferation of CD8þT cells was




















































































































































































Phenotypic characteristics of BM
CD8þ T cells from multiple myeloma
(MM) patients. A–C, PBMCs and
BMMCs from 47 newly diagnosed
multiple myeloma patients, and
BMMCs from 9 EMZL patients with-
out BM involvement, 4 MGUS
patients, and 4 SMM patients were
analyzed by flow cytometry. The rel-
ative frequency of PD-1þ cells among
BM CD8þ T cells from multiple mye-
loma patients was compared with
paired PB CD8þ T cells (A), BM CD8þ
T cells from EMZL patients (B), and
BM CD8þ T cells from MGUS or SMM
patients (C). D and E, The relative
frequency of Tim-3þ, Lag-3þ, or
TIGITþ cells among PD-1þ cells was
compared with the frequencies
among PD-1 cells in BM CD8þ T cells
from multiple myeloma patients (D).
Representative figures from a single
multiple myeloma patient are pre-
sented (E). F and G, The relative
frequency of EomeshiT-betlo cells
among PD-1þ cells was compared
with the frequencyamongPD-1 cells
in BM CD8þ T cells from multiple
myeloma patients (n ¼ 23; F). Rep-
resentative figures from a
single multiple myeloma patient
are presented (G). H, The relative
frequency of TCF-1þ cells among
PD-1þ cells was compared with the
frequency among PD-1 cells in BM
CD69þCD8þ T cells from multiple
myelomapatients (n¼ 27). Statistical
analysis was performed using the
Mann–Whitney U test or Wilcoxon
matched-pairs signed rank test. Error
bars, SD. , P < 0.05; , P < 0.0001.
MM, multiple myeloma.
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BM CD8þ T cells from multiple myeloma patients (Fig. 5A and B),
whereas the proliferation of BM CD8þ T cells from DLBCL or HL
patients was significantly restored by anti–PD-1 (Fig. 5A). Combined
blockade of PD-1 and other immune-checkpoint receptors such as
Tim-3, Lag-3, or TIGIT did not significantly increase the anti–CD3-
stimulated proliferation of BM CD8þ T cells from multiple myeloma
patients (Supplementary Fig. S9A and S9B). We confirmed failure of
anti–PD-1-induced reinvigoration of CD8þ T cells by stimulation
of BMMCs from multiple myeloma patients with HLA-A0201–
restricted myeloma antigen peptides, including NY-ESO-1157-165 and
HM1.2422-30 peptides. Anti–PD-1 did not significantly restore the
proliferation of BM CD8þ T cells from HLA-A2þ multiple myeloma
patients (Fig. 5C and D). When this assay was performed with
BMMCs from HLA-A2þ patients with EMZL, MGUS, or SMM,
proliferation of BMCD8þ T cells was not enhanced by PD-1 blockade
(Supplementary Fig. S10A–S10D). These data demonstrate that block-
ing PD-1 is not sufficient to restore the function of BM CD8þ T cells
from multiple myeloma patients.
Reinvigoration of BM CD8þ T cells from multiple myeloma
patients by PD-1 blockade in the presence of TGFb inhibitors
We hypothesized that blockade of an additional T-cell inhibitory
factor is required to restore the function of BM CD8þ T cells, even if
PD-1/PD-L1 interaction is blocked. It has been known that TGFb,
which is actively secreted by malignant plasma cells and BM stromal
cells (28), can inhibit T-cell responses (29). We confirmed that the
major source of TGFb1 is plasma cells including myeloma cells
among BMMCs from multiple myeloma patients, and the number
of TGFb1-producing plasma cells, including myeloma cells, is
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Figure 2.
Phenotypic characteristics of myeloma antigen–specific CD8þ T cells from the BM of multiple myeloma patients. A–E, BMMCs from newly diagnosed HLA-A2þ
multiple myeloma patients were stained with HLA-A0201 NY-ESO-1157-165 (SLLMWITQC) and HM1.2422-30 (LLLGIGILV) dextramers and analyzed by flow cytometry.
Representative figures are presented (A). The relative frequencyof PD-1þ cells inNY-ESO-1157-165 dextramer
þ (n¼ 20) or HM1.2422-30 dextramerþ (n¼4)CD8þT cells
was comparedwith total BMCD8þ T cells (B). Representative figures are presented (C). AmongNY-ESO-1157-165 dextramer
þ or HM1.2422-30 dextramer
þCD8þ T cells,
the relative frequency of Tim-3þ, Lag-3þ, or TIGITþ cells among PD-1þ cells was compared with the frequency among PD-1 cells (D). Representative figures are
presented (E). Among NY-ESO-1157-165 dextramer
þ (n ¼ 18) or HM1.2422-30 dextramerþ (n ¼ 4) CD8þ T cells, the relative frequency of EomeshiT-betlo cells in PD-1þ
cells was compared with PD-1 cells (F). Error bars represent SD. Statistical analysis was performed using theWilcoxon matched-pairs signed rank test.  , P < 0.01;
 , P < 0.001;  , P < 0.0001.
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that from EMZL, MGUS, and multiple myeloma patients (Fig. 6A).
Next, we examined the effect of TGFb1 or TGFb1 blocking anti-
bodies on the phenotype and differentiation of BM CD8þ T cells
from multiple myeloma patients. TGFb1 increased PD-1 expression
but reduced T-bet expression in BM CD8þ T cells (Supplementary
Fig. S11A and S11B). Anti-TGFb1 blocking antibodies decreased
the expression of PD-1 in BM CD8þ T cells from multiple myeloma
patients (Fig. 6B) and increased the expression of T-bet (Fig. 6C)
and TCF-1 (Fig. 6D).
We investigated whether blocking TGFb signaling enhances rein-
vigoration of BMCD8þT cells frommultiplemyeloma patients. CTV-
labeled BMMCs were stimulated with anti-CD3 in the presence of
anti–PD-1 and/or anti-TGFb1 blocking antibodies, and the prolifer-
ation of CD8þ T cells was evaluated. The combined blockade of PD-1
and TGFb significantly increased the proliferation of BMCD8þT cells
from multiple myeloma patients (Fig. 6E–G). However, the mitotic
index of multiple myeloma-derived BM CD8þ T cells in the presence
of anti–PD-1 antibody and TGFb inhibitors was not at the level of BM
CD8þ T cells from EMZL, MGUS, or SMM patients or PB CD8þ T
cells frommultiple myeloma patients or healthy donors in the absence
of anti–PD-1 antibody and TGFb inhibitors (Supplementary
Fig. S12A–S12D). In addition, combined blockade of PD-1 and TGFb
did not increase the proliferation of BM CD8þ T cells from EMZL,
MGUS, and SMM patients (Supplementary Fig. S13A–S13D) and PB
CD8þ T cells from normal healthy donors or multiple myeloma
patients (Supplementary Fig. S13E and S13F). When stimulated with
anti-CD3, the production of IFNg and TNF by BM CD8þ T cells was
also rescued by combined blockade of PD-1 and TGFb (Supplemen-
tary Fig. S14A–S14C).
In addition, combination of anti–PD-1 antibody and TGFb
inhibitors increased proliferative responses of BM CD8þ T cells
from HLA-A2þ multiple myeloma patients stimulated with a
mixture of HLA-A0201–restricted myeloma antigen peptides
(NY-ESO-1157-165 and HM1.2422-30 peptides; Fig. 6H–J). However,
PD-1 and/or TGFb blockade–induced increase in CD8þ T-cell
proliferation was not observed in the absence of antigen stimula-
tion (Supplementary Fig. S15A and S15B). When BMMCs from
HLA-A2þ patients with EMZL, MGUS, or SMM were stimulated
with a mixture of HLA-A0201–restricted myeloma antigen pep-
tides, PD-1 and/or TGFb blockade did not enhance CD8þ T-cell
proliferation in BMMCs from EMZL, MGUS, and SMM patients
(Supplementary Fig. S16A–S16D).
Enhancement in proliferative response of BM CD8þ T cells to
neoantigenwas also investigated forKRASmutation. TheKRASG12D
mutation was identified in two multiple myeloma patients, and their
BMMCs were stimulated with a mixture of 9 overlapping peptides
(9-mer) spanning KRAS codon 12 of wild-type (YKLVVV-

































































































































































Expression of PD-L1 onmalignant plasma cells and immune cells from the BMofmultiplemyelomapatients.A, The relative frequency ofmalignant plasma cells (MPC;
CD38þCD319þCD45CD19) among BMMCs frommultiple myeloma patients (n¼ 38) was analyzed. B and C, The relative frequency of PD-L1þ cells was analyzed in
both malignant plasma cells (CD38þCD319þCD45CD19) and normal plasma cells (NPC; CD38þCD319þCD45þCD19þ) in BMMCs from multiple myeloma patients
who had detectable numbers of normal plasma cells (n¼ 24). Representative histograms are presented (C).D, The relative frequency of PD-L1þ cells was analyzed in
malignant plasma cells among BMMCs frommultiple myeloma patients (n¼ 38) and normal plasma cells from EMZL patientswithout BM involvement (n¼ 8). E, The
relative frequency of PD-L1þ cells was analyzed in CD11cþ dendritic cells (CD45þCD14CD3CD11cþHLA-DRþ, left), B cells (CD45þCD14CD3CD19þHLA-DRþ,
middle), and monocytes (CD45þCD3CD14þ, right) among BMMCs from multiple myeloma patients (n ¼ 38) and EMZL patients without BM involvement (n ¼ 8).
Statistical analysis was performed using the Mann–Whitney U test or Wilcoxon matched-pairs signed rank test.  , P < 0.01;  , P < 0.001;  , P < 0.0001. MM,
multiple myeloma.
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mutant-type (YKLVVVGADGVGKSALT; from YKLVVVGAD to
DGVGKSALT). As a result, the proliferation of BM CD8þ T cells
was efficiently increased by the combined blockade of PD-1 and
TGFb in the presence of mutant-type KRAS peptides. When BM
CD8þ T cells were stimulated by wild-type KRAS peptides, their
proliferation was ignorable and not enhanced by the combined
blockade of PD-1 and TGFb (Fig. 6K). Importantly, there was no
considerable proliferation of BM CD8þ T cells from multiple
myeloma patients without KRAS G12D mutation following stim-
ulation with wild-type or G12D mutant–type peptides (Supplemen-
tary Fig. S17A), and their proliferation was not enhanced by the
blockade of PD-1 and/or TGFb (Supplementary Fig. S17B–S17E).
When BMMCs from HLA-A2þ multiple myeloma patients were
stimulated with NY-ESO-1157-165 and HM1.2422-30 peptides for
3 weeks, combined blockade of PD-1 and TGFb significantly
increased the frequency of NY-ESO-1157-165 or HM1.2422-30
HLA-A0201 multimerþ CD8þ T cells, although PD-1 blockade
alone was not sufficient to increase their frequency (Supplementary
Fig. S18A–S18F). In contrast, the frequency of HCMV pp65495-503–
specific CD8þ T cells was not influenced by PD-1 or TGFb blockade
(Supplementary Fig. S18G–S18I). Combined blockade of PD-1 and
TGFb robustly enhanced the target cell killing capacity (Supple-
mentary Fig. S19A–S19C), as well as the production of IFNg and
TNF (Supplementary Fig. S19D–S19F) in coculture assays using
NY-ESO-1157-165–specific PD-1
þCD8þ T-cell lines. In line with
this, combined treatment with anti–PD-1 and anti-TGFb signifi-
cantly reduced the tumor size in a mouse model of MOPC315.BM
plasmacytoma (Fig. 6L; Supplementary Fig. S20). Thus, PD-1
blockade reinvigorates BM CD8þ T cells from multiple myeloma
patients in the presence of TGFb inhibitors.
Discussion
PD-1/PD-L1 blockade that reinvigorates exhausted T cells has been
approved for the treatment of various solid tumors or hematologic





















































































































































































































Impaired proliferation and cytokine production by BMCD8þ T cells frommultiple myelomapatients.A andB,BMMCs frommultiplemyeloma (n¼ 22), MGUS (n¼ 4),
or SMM (n ¼ 1) patients were labeled with CTV and stimulated with anti-CD3 (1 ng/mL) for 108 hours. The mitotic index of CD8þ T cells was analyzed (A).
Representative figures are presented (B).C,BMMCs frommultiple myeloma (n¼ 7), MGUS (n¼ 4), or SMM (n¼ 2) patients were stimulatedwith anti-CD3 (1 mg/mL)
and anti-CD28 (1 mg/mL) for 30 hours, and intracellular cytokine staining for IFNg and TNFwas performed. The percentages of IFNgþ cells (left), TNFþ cells (middle),
and double-positive (IFNgþTNFþ) cells (right) among BMCD8þ T cells were analyzed.D and E,BMMCs frommultiplemyeloma (n¼ 22), DLBCLwith BM involvement
(n¼ 10), or HL with BM involvement (n¼ 2) patients were labeled with CTV and stimulated with anti-CD3 (1 ng/mL) for 108 hours. The mitotic index of CD8þ T cells
was analyzed (D). Representative figures arepresented (E).F,BMMCs frommultiplemyeloma (n¼ 7) orDLBCLwithBM involvement (n¼7) patientswere stimulated
with anti-CD3 (1 mg/mL) and anti-CD28 (1 mg/mL) for 30 hours, and intracellular cytokine staining for IFNg and TNF was performed. The percentages of IFNgþ cells
(left), TNFþ cells (middle), and double-positive (IFNgþTNFþ) cells (right) among BM CD8þ T cells were analyzed. Error bars, SD. Statistical analysis was performed
using the Mann–Whitney U test.  , P < 0.05;  , P < 0.01;  , P < 0.001;  , P < 0.0001. MM, multiple myeloma; N.S., not significant.
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blockade with conventional chemotherapy or targeted therapy has
enhanced clinical efficacy in clinical trials for patients with non–small
cell lung cancer (30) or renal cell carcinoma (31). However, in a clinical
trial of multiple myeloma patients, anti–PD-1 monotherapy did not
result in a clinical response (11). Furthermore, clinical trials of
combining PD-1 blockade with immunomodulatory drugs (32) or
anti-CD38 monoclonal antibody (33) failed to demonstrate clinical
benefits in multiple myeloma patients. To enhance the clinical efficacy
of ICIs in multiple myeloma, an elaborate characterization of BM
CD8þ T cells in multiple myeloma patients is essential.
In the present study, we demonstrated that BM CD8þ T cells from
multiple myeloma patients express increased levels of PD-1 and a
terminally differentiated phenotype with impaired proliferation and
effector functions. Using NY-ESO-1157-165 and HM1.2422-30 multi-
mers, we demonstrated that myeloma antigen–specific CD8þ T cells
also overexpress PD-1. Although PD-1 blockade alone did not rein-
vigorate BM CD8þ T cells, the combined blockade of PD-1 and TGFb
successfully rescued the cells from exhaustion.
Several studies have reported the expression of immune-checkpoint
inhibitory receptors in T cells from multiple myeloma patients. The
expression of PD-1 has been reported to be significantly upregulated
onBMCD8þT cells frommultiplemyeloma patients (7–9).Moreover,
CD4þ and CD8þ T cells from relapsed multiple myeloma patients
expressed significantly higher levels of PD-1 than those fromMGUSor
newly diagnosed multiple myeloma patients (8). However, a recent
study reported thatmultiple myeloma patients have clonally expanded
T cells with low levels of PD-1 expression (12). In the present study, the
expression of PD-1 was upregulated in total CD8þT cells from the BM
of multiple myeloma patients, corroborating the results from earlier
studies (7–9). In addition, we showed for the first time that the
expression of PD-1 was upregulated in myeloma antigen–specific
CD8þ T cells, using MHC-I multimers loaded by myeloma antigenic
peptides.
Two heterogeneous subsets of exhausted T cells were identified
according to the expression of T-bet and Eomes in a mouse model of
chronic lymphocyte choriomeningitis virus infection (34). During
chronic infection, T-bethiEomesloCD8þ T cells maintain a prolifer-
ative potential and cytokine secretion, whereas EomeshiT-betloCD8þ
T cells exhibit poor proliferative potential and cytokine secretion,
indicating that they are terminally differentiated cells. Moreover,
EomeshiT-betloCD8þ T cells have limited potential with anti–PD-1-
induced reinvigoration (20, 23). In our data, BM PD-1þCD8þ T cells
from multiple myeloma patients had skewed expression toward
EomeshiT-betlo. BM CD8þ T cells in multiple myeloma patients
also exhibited reduced cytokine secretion and proliferation upon
activation of T-cell receptor signals. Moreover, proliferation of BM
CD8þ T cells from multiple myeloma patients was not reinvigorated
by PD-1 blockade.
The TGFb signaling pathway contributes to tumor progression by
diverse mechanisms, including proliferation and differentiation, epi-
thelial–mesenchymal transition, invasion and migration, and the







































































Effect of PD-1 blockade on the proliferation of BM CD8þ T cells from multiple myeloma patients. A and B, BMMCs from multiple myeloma (n¼ 22), DLBCL with BM
involvement (n ¼ 10), or HL with BM involvement (n ¼ 2) patients were labeled with CTV and stimulated with anti-CD3 (1 ng/mL) in the presence of anti–PD-1 or
isotype control antibody for 108 hours. The ratio of mitotic index with and without anti–PD-1 (mitotic index with anti–PD-1/mitotic index with isotype control
antibody)was assessed (A). Representative figures are presented (B).C andD,BMMCs fromHLA-A0201þmultiplemyelomapatients (n¼ 13)were labeledwith CTV
and stimulated with a mixture of NY-ESO-1157-165 (SLLMWITQC) and HM1.2422-30 (LLLGIGILV) peptides in the presence of anti–PD-1 or isotype control antibody for
144 hours. The ratio of mitotic index with andwithout anti–PD-1 (mitotic index with anti–PD-1/mitotic index with isotype control antibody) was calculated as follows:
(mitotic indexwith anti–PD-1)/(mitotic indexwith controls) (C). Representative figures are presented (D). Error bars represent SD. Statistical analysiswas performed
by Wilcoxon matched-pairs signed rank test.  , P < 0.01. MM, multiple myeloma; N.S., not significant.
Kwon et al.
Clin Cancer Res; 26(7) April 1, 2020 CLINICAL CANCER RESEARCH1652
on August 5, 2021. © 2020 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 





















































































































































































































































Stimulation with KRAS G12D
Galunisertib
K Stimulation with KRAS wild typeNo stimulation













Reinvigoration of BMCD8þ T cells frommultiple myeloma patients by PD-1 blockade in the presence of TGFb inhibitors.A, The number of TGFb1-producing cellswas
analyzed in BMMCs frommultiple myeloma patients (n¼ 7), MGUS (n¼ 4), SMM (N¼ 3), or EMZ (n¼ 7) by intracellular cytokine staining.B–D,BMMCs frommultiple
myeloma patients (n¼ 9) were cultured for 36 hours in the presence of anti-CD3 (1 ng/mL) and/or anti-TGFb1, and the frequency of PD-1þ (B), T-betþ (C), or TCF-1þ
(D) cells amongBMCD8þT cellswas analyzed.E–G,BMMCs frommultiplemyelomapatients (n¼9)were labeledwith CTVand stimulatedwith anti-CD3 (1 ng/mL) in
the presence of anti–PD-1, TGFb inhibitors such as anti–TGFb1-neutralizing antibody (F) or galunisertib (G), or isotype control antibody for 108 hours. Representative
histograms are presented (E).H–J,BMMCs fromHLA-A2þmultiplemyeloma patients (n¼ 8) were labeledwith CTV and stimulatedwith amixture of NY-ESO-1157-165
(SLLMWITQC) andHM1.2422-30 (LLLGIGILV) peptides in the presence of anti–PD-1, TGFb inhibitors such as anti–TGFb1-neutralizing antibody (I) or galunisertib (J), or
isotype control antibody for 144 hours. Representative figures are presented (H). The ratio of mitotic index with and without anti–PD-1 and TGFb inhibitors (mitotic
index with anti–PD-1 and TGFb inhibitors/mitotic index with isotype control antibody) was calculated as follows: (mitotic index with anti–PD-1 and TGFb inhibitors)/
(mitotic indexwith controls). Lines represent thedata fromeachpatient, and bars representmeanvalues.K,BMMCs fromamultiplemyelomapatient harboringKRAS
G12D mutation were labeled with CTV and stimulated with a mixture of 9 overlapping peptides (9-mer) spanning KRAS codon 12 of wild-type (YKLVVVGAGGVGK-
SALT) or G12D mutant-type (YKLVVVGADGVGKSALT) in the presence of anti–PD-1, TGFb inhibitors such as anti–TGFb1-neutralizing antibody or galunisertib, or
isotype control for 144 hours. L,MOPC315.BMmyeloma cells were subcutaneously injected into Balb/c mice (n¼ 11 for each group), and isotype control antibodies,
anti–PD-1 antibodies, anti-TGFb antibodies, or a combination of anti–PD-1 with anti-TGFb antibodies were administered every 3 days from 11 days after tumor
injection. Tumor volume was measured 20 days after tumor injection. Error bars, SD. Statistical analysis was performed using the Mann–Whitney U test. P values
were indicated. Statistical analysis was performed using theMann–WhitneyU test orWilcoxonmatched-pairs signed rank test.  , P < 0.05;  , P < 0.01;  , P < 0.001;
 , P < 0.0001. MM, multiple myeloma; N.S., not significant.
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addition, TGFb promotes angiogenesis and stimulates the generation
of cancer-associated fibroblasts in the tumor microenvironment (35).
TGFb also inhibits antitumor immune responses, as TGFb directly
inhibits the proliferation and activities of macrophages and NK cells,
CD4þ helper T cells, and CD8þ cytotoxic T cells, and promotes the
proliferation and function of regulatory T cells and myeloid-derived
suppressor cells (36). Moreover, TGFb1 upregulates PD-1 on tumor
reactive T cells and suppressed antitumor T-cell immunity (37).
Targeting the TGFb pathway is an emerging strategy in cancer
therapy. Galunisertib (LY2157299, Eli Lilly), a small-molecule inhib-
itor of TGFb receptor I kinase, has an acceptable safety profile in phase
I and II clinical trials (38–40). Several clinical trials with galunisertib
are ongoing in hepatocellular carcinoma (NCT01246986; ref. 41) and
pancreatic adenocarcinoma (NCT01373164; ref. 42). Another TGFb
kinase inhibitor, vactosertib (TEW-7197, MedPacto), is currently in
clinical trials for relapsed or refractory multiple myeloma in combi-
nation with pomalidomide (NCT03143985).
Blocking immune-checkpoint receptors and TGFb is a promising
combination strategy for enhancing antitumor T-cell responses (43).
TGFb has been demonstrated to attenuate antitumor immune
responses induced by PD-L1 blockade in bladder cancer patients (13).
In addition, coinhibition of TGFb and PD-1 promotes robust tumor
regression in mouse tumor models (13, 14, 44). Clinical trials com-
bining galunisertib with ICIs are currently under way in patients with
non–small cell lung cancer, hepatocellular carcinoma, and pancreatic
cancer (NCT02423343 and NCT02734160). Vactosertib is also
expected to begin clinical trials in combination with anti–PD-L1 or
anti–PD-1 for non–small cell lung cancer, gastric cancer, and colo-
rectal cancer. In our data, blocking the TGFb signal significantly
enhanced anti–PD-1-induced functional restoration in BM CD8þ
T cells in multiple myeloma patients, suggesting a clinical trial testing
coblockade of TGFb and PD-1 in patients with multiple myeloma.
There are a few limitations to our study. First, the expression of
myeloma antigens (NY-ESO-1 andHM1.24) inmyeloma cells was not
examined, although myeloma antigen–specific CD8þ T cells were
studied in multiple myeloma patients. HM1.24 is widely expressed
in myeloma cells (45, 46). However, NY-ESO-1 is known to be
expressed in < 30% of multiple myeloma patients (45–47). Compared
with this low positive rate for NY-ESO-1 expression in historic data,
NY-ESO-1157-165–specific CD8
þ T cells were detected with a relatively
high rate (20/29, 69.0%) in the present study. Therefore, investigating
both myeloma antigen expression and myeloma antigen–specific
CD8þ T cells in same patients is necessary in the future study. Second,
although the frequency of myeloma antigen–specific cells was very low
in BM CD8þ T cells from EMZL, MGUS, and SMM patients (Sup-
plementary Fig. S6), CD8þ T-cell proliferation in the presence of
myeloma antigen peptides was higher in BMMCs fromEMZL,MGUS,
and SMMpatients than inmultiplemyeloma patients (Supplementary
Fig. S21). These data indicate that there might be antigen-nonspecific
CD8þ T-cell proliferation in our assay system, although BMMCs were
ex vivo stimulated with myeloma antigen peptides. Antigen-
nonspecific CD8þ T-cell proliferation might result from bystander
activation. Third, a relatively low number of MHC-I multimerþCD8þ
T cells may hamper accurate phenotyping. Phenotypic analysis of
myeloma antigen–specific CD8þ T cells requires caution particularly
when the frequency of MHC-I multimerþCD8þ T cells is low.
In summary, BM CD8þ T cells and myeloma antigen–specific
CD8þ T cells express increased levels of PD-1 and have a terminally
exhausted phenotype in multiple myeloma patients. Under TGFb
inhibition, anti–PD-1 reinvigorates BM CD8þ T cells from multiple
myeloma patients, but PD-1 blockade alone does not restore the
function of BM CD8þ T cells. Blocking both TGFb and PD-1 can
be a promising therapeutic strategy for the treatment of multiple
myeloma.
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